119 related articles for article (PubMed ID: 15848601)
1. Inhibition of plasminogen activator inhibitor-1 by angiotensin II receptor blockers on cyclosporine-treated renal allograft recipients.
Ishikawa A; Ohta N; Ozono S; Kawabe K; Kitamura T
Transplant Proc; 2005 Mar; 37(2):994-6. PubMed ID: 15848601
[TBL] [Abstract][Full Text] [Related]
2. Prevention of interstitial fibrosis of renal allograft by angiotensin II blockade.
Ishikawa A; Tanaka M; Ohta N; Ozono S; Kitamura T
Transplant Proc; 2006 Dec; 38(10):3498-501. PubMed ID: 17175314
[TBL] [Abstract][Full Text] [Related]
3. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
Omoto K; Tanabe K; Tokumoto T; Shimmura H; Ishida H; Toma H
Transplantation; 2003 Oct; 76(8):1170-4. PubMed ID: 14578748
[TBL] [Abstract][Full Text] [Related]
4. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
[TBL] [Abstract][Full Text] [Related]
5. Effect of angiotensin II type-1 receptor blockers on stable allograft kidneys: prospective randomized study.
Nouri-Majalan N; Ghafari A; Moghaddasi S
Transplant Proc; 2009 Sep; 41(7):2832-4. PubMed ID: 19765449
[TBL] [Abstract][Full Text] [Related]
6. Effect of nifedipine on renal allograft function and survival beyond one year.
Shin GT; Cheigh JS; Riggio RR; Suthanthiran M; Stubenbord WT; Serur D; Wang JC; Rubin AL; Stenzel KH
Clin Nephrol; 1997 Jan; 47(1):33-6. PubMed ID: 9021239
[TBL] [Abstract][Full Text] [Related]
7. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
Montanaro D; Gropuzzo M; Tulissi P; Vallone C; Boscutti G; Mioni R; Risaliti A; Baccarani U; Adani GL; Sainz M; Bresadola F; Mioni G
Transplant Proc; 2005 Mar; 37(2):991-3. PubMed ID: 15848600
[TBL] [Abstract][Full Text] [Related]
8. Long-term renoprotective effect of candesartan in renal transplant patients.
Ishii T; Yasuda M; Itami Y; Hayashi T; Uemura H; Nose K; Nishioka T
Transplant Proc; 2012 Apr; 44(3):638-41. PubMed ID: 22483458
[TBL] [Abstract][Full Text] [Related]
9. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
Fogari R; Zoppi A; Mugellini A; Maffioli P; Lazzari P; Derosa G
Hypertens Res; 2011 Dec; 34(12):1321-6. PubMed ID: 21814211
[TBL] [Abstract][Full Text] [Related]
10. Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors.
Agirbasli M; Cincin A; Baykan OA
J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):22-6. PubMed ID: 18404606
[TBL] [Abstract][Full Text] [Related]
11. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
Kanno Y; Takenaka T; Nakamura T; Suzuki H
Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
[TBL] [Abstract][Full Text] [Related]
12. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of normotensive renal transplant recipients with microalbuminuria and effects of angiotensin II type I receptor antagonist on urinary albumin excretion.
Satoh S; Horikawa Y; Kakinuma H; Tsuchiya N; Wang L; Kato T; Habuchi T
Int J Urol; 2004 Aug; 11(8):585-91. PubMed ID: 15285746
[TBL] [Abstract][Full Text] [Related]
14. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
Willemsen JM; Rabelink TJ; Boer P; Gaillard CA
J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study.
Koh KK; Chung WJ; Ahn JY; Han SH; Kang WC; Seo YH; Ahn TH; Choi IS; Shin EK
Atherosclerosis; 2004 Nov; 177(1):155-60. PubMed ID: 15488878
[TBL] [Abstract][Full Text] [Related]
16. Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients.
Uchida J; Machida Y; Iwai T; Iguchi T; Kamada Y; Naganuma T; Kumada N; Kim T; Kawashima H; Nakatani T
J Nephrol; 2011; 24(4):515-21. PubMed ID: 21240871
[TBL] [Abstract][Full Text] [Related]
17. Examination of the effect of changing to azilsartan from candesartan in renal transplant patients.
Ishii T; Yasuda M; Saito Y; Mori Y; Hayashi T; Uemura H; Nose K; Nishioka T
Transplant Proc; 2014; 46(2):492-5. PubMed ID: 24655997
[TBL] [Abstract][Full Text] [Related]
18. Valsartan-induced hematocrit changes in renal transplant patients.
Flores CA; Ardiles LG; Aros CA; Muñoz CC; Schneider HO; Ramírez JA; Jerez V; Valderrama MG; Mezzano SA
Transplant Proc; 2005 Apr; 37(3):1586-8. PubMed ID: 15866681
[TBL] [Abstract][Full Text] [Related]
19. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
Fogari R; Zoppi A; Salvadeo SA; Mugellini A; Lazzari P; Santoro T; Derosa G
Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
[TBL] [Abstract][Full Text] [Related]
20. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy.
Kanda H; Kubo K; Tateishi S; Sato K; Yonezumi A; Yamamoto K; Mimura T
Lupus; 2005; 14(4):288-92. PubMed ID: 15864915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
